NCT06679283 Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF)
| NCT ID | NCT06679283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bern |
| Condition | Peri-Implantitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-02-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Platelet-rich fibrin (PRF) is a second-generation platelet concentrate used for tissue and bone regeneration. PRF releases growth factors such as TGF-β, PDGF, VEGF, IGF, and FGF, which are known to promote wound healing and bone regeneration. Thus, PRF may offer a promising therapeutic approach for peri-implantitis treatment. Numerous studies have reported beneficial effects of PRF on bone regeneration, bone augmentation, soft tissue healing, and ridge preservation. In infrabony periodontal defects, PRF has shown significant improvements in pocket depth reduction, clinical attachment level (CAL) gain, and bone fill. However, a recent systematic review highlighted that evidence supporting PRF use in peri-implantitis remains limited, primarily due to a lack of adequately designed studies. Therefore, the aim of this project is to investigate whether PRF enhances regeneration in peri-implantitis defects. Specifically, it will assess whether surgical debridement of peri-implantitis defects-including electrochemical detoxification of implant surfaces using GalvoSurge-combined with PRF clot and membrane placement, improves treatment outcomes compared to surgical debridement and detoxification using GalvoSurge alone. For this purpose, implants with peri-implantitis defects of comparable size will be randomly assigned to either the test or control group. After 12 months, implants will be clinically evaluated for radiographic defect fill, reduction in probing pocket depth (PPD), and bleeding on probing (BOP). The objective of this project is to verify, both radiographically and clinically, whether adjunctive PRF application enhances tissue regeneration and healing of peri-implantitis defects compared to open flap debridement (OFD) alone.
Eligibility Criteria
Inclusion Criteria: 1. One or more peri-implant sites with PPD ≧ 5 mm combined with BOP/suppuration and 2. Peri-implant marginal bone loss, defined as a crater like defect ≧ 3 mm as assessed from intraoral radiographs 3. Good oral hygiene i.e. a plaque index \<20% 4. Written informed consent Exclusion Criteria: 1. History of chronic inflammatory disease 2. Severe systemic diseases 3. Medically confirmed diagnosis of diabetes mellitus 4. Anti-inflammatory prescription including prednisone 5. Smoking \> 5 cigarettes 6. Pregnant or lactating women 7. \< 18 years of age
Contact & Investigator
Giovanni Salvi, MD
PRINCIPAL INVESTIGATOR
University of Bern
Frequently Asked Questions
Who can join the NCT06679283 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peri-Implantitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06679283 currently recruiting?
Yes, NCT06679283 is actively recruiting participants. Contact the research team at alexandra.staehli@unibe.ch for enrollment information.
Where is the NCT06679283 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT06679283 clinical trial?
NCT06679283 is sponsored by University of Bern. The principal investigator is Giovanni Salvi, MD at University of Bern. The trial plans to enroll 40 participants.